Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held AAV gene therapy based company founded in 2001 to advance the work of Dr. Richard Jude Samulski, former Director of the Gene Therapy Center at the University of North Carolina (UNC) from the lab into the clinic. Dr. Samulski was the first to clone AAV for therapeutic purposes. Since AskBio’s inception almost two decades ago, Dr. Samulski’s efforts have joined those of a group of widely acclaimed researchers and clinicians.

Research Grants 6 show all


$157K
2005

$604.6K
2008

$2.9M
2010

$270K
2014

Patents 26show all

  • 15
    C12N - Microorganisms or enzymes
  • 14
    A61K - Preparations for medical, dental, or toilet purposes
  • 13
    C07K - Peptides

Clinical Trials 3show all

2Phase 11Phase 1/Phase 2

SEC Filings show all


2
D

Contact Information

45 N. Chatham Parkway
Chapel Hill, NC 27517
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$235,000,00051-1002019-04-11Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2019-04-11$235,000,000Private EquityTPG Capital Asia, Vida Ventures

SEC Form D Funding Events

DateOfferedSoldType
2006-01-26Unknown Unknown Other (Paper Filing)